Effect of cefepime (CFPM) or meropenem (MEPM) for febrile neutropenia patients with lung cancer. Randomized phase II study.

Not Applicable

• Conditions: Febrile neutropenia

• Registration Number: JPRN-UMIN000005275
• Lead Sponsor: OGIK(Lung oncology group in Kyushu)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-03-18
• Study Completion: 2013-01-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 46

Inclusion Criteria

Not provided

Exclusion Criteria

1. Patient who is too severely ill 2. A history of cardiac failure, renal failure, or liver damage. 3. A known history of hypersensitivity to cephalosporins 4. A known history of allergy 5. Patient who demonstrated positive for skin reaction test ( if skin reaction test was done) 6. Patient who is not evaluated for response 7. Pregnant or lactating women. 8. Patient administered with sodium valproate 9. Patients administered with prohibiting medication (such as other antibiotics, gamma-globulin, corticosteroid, furosemide) 10.patient who is judged as an inappropriate case by the doctor in charge

Study & Design

• Study Type: Interventional
• Study Design: Not specified